|
|||||
|
|
| 2002年～2004年长江流域6城市157家医院心血管系统药物利用分析 | |
| 引用本文： | 冯琳,侯孝云,戴惠珍,陶琳.2002年～2004年长江流域6城市157家医院心血管系统药物利用分析[J].中国药房,2006,17(2):115-119. |
| 作者姓名： | 冯琳 侯孝云 戴惠珍 陶琳 |
| 作者单位： | 1. 南京医科大学附属第一医院,南京市,210029 2. 江苏省医药情报研究所,南京市,210004 3. 上海市食品药品监督管理局科技情报研究所,上海市,200040 |
| 摘 要： | 目的:评价2002年～2004年长江流域6城市157家医院心血管系统药物应用状况及趋势。方法:利用金额排序法和用药频度排序法,对长江流域6城市157家医院的心血管系统用药进行统计、分析。结果:2004年6城市心血管系统用药总金额达13.6亿元,较2002年增长58.8%,其中抗心绞痛药及血管扩张药、抗血栓药、抗高血压药3个亚类用量3年平均占整个心血管用药的84.1%。在金额排序和用药频度排序前列中,主要包括钙拮抗药、血管紧张素转化酶抑制药、硝酸酯、β受体阻滞药和中药制剂类产品。结论:用药依从性好、不良反应发生率低、疗效确切、日均费用低的药物已成为临床医师治疗心血管疾病的首选。 |
| 关 键 词： | 心血管系统药物 金额 用药频度 |
| 文章编号： | 1001-0408(2006)02-0115-05 |
| 收稿时间： | 07 25 2005 12:00AM |
| 修稿时间： | 10 20 2005 12:00AM |
Analysis on Cardiovascular Drugs Used in 157 Hospitals of 6 Cities in the Yangtze River Valley during the Period of 2002～2004 |
|
| FENG Lin,HOU Xiaoyun,DAI Huizhen,TAO Lin.Analysis on Cardiovascular Drugs Used in 157 Hospitals of 6 Cities in the Yangtze River Valley during the Period of 2002～2004[J].China Pharmacy,2006,17(2):115-119. | |
| Authors: | FENG Lin HOU Xiaoyun DAI Huizhen TAO Lin |
| Institution: | 1.The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;2.Research Institute for Medicine Information of Jiangsu Province, Nanjing 210004,China;3. Research Institute for Science and Technology Information of Shanghai FDA, Shanghai 200040, China |
| Abstract: | OBJECTIVE: To evaluate the current situation and the trend of cardiovascular drugs used in 6 cities in the Yangtze river valley between 2002 and 2004.METHODS:Consumption of cardiovascular drugs used in 157 hospitals of 6 cities in the Yangtze river valley were analyzed by the way of sum and DDDs ranking. RESULTS:The total annual cost of the cardiovascular drugs used in 6 cities was 13.6 billion yuan in 2004, increasing by 58.8%, as compared with that in 2002.The total average consumption of anti-anginal and vasodilating agents, antithrombotic agents and antihypertensives accounted for 84.1% of the total cost in 3 years.CCB, ACEI, Nitrate esters,β-blockers and Chinese medicines dominated in the ranking of sum and DDDs.CONCLUSION: Right medicines with higher patient compliance rates, lower ADR occurrence, more certain therapeutic effect and economical daily cost have become the preferable choices for clinical physicians. |
| Keywords: | Cardiovascular drugs Cost DDDs |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |